linjc16/ctgov huggingface dataset:
The Impact of Active Nurse Participation on Adenoma Detection During Routine Colonoscopy

Study Overview
=================
Brief Summary
-----------------
Hypothesis-- Nurse observation in addition to the colonoscopist while withdrawing the colonoscope from the cecum leads to a greater adenoma detection rate. Methods- Patients presenting for screening colonoscopy are randomized to nurse observation or usual practice. Risk factors for adenoma development and the adenoma detection rate in each group will be evaluated.

Official Title
-----------------
The Impact of Active Nurse Participation on Adenoma Detection During Routine Colonoscopy

Conditions
-----------------
Adenoma

Intervention / Treatment
-----------------
* Procedure: nurse observation during colonoscope withdrawal


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: performance of screening colonoscopy Exclusion Criteria: history of inflammatory bowel disease, gastrointestinal bleeding

Ages Eligible for Study
-----------------
Minimum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Nurse participation during colonoscope withdrawal | Procedure: nurse observation during colonoscope withdrawal<br>* nurse observation during colonoscope withdrawal<br>|
| No Intervention: 2<br>usual colonoscopy practice | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adenoma detection rate |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
colonoscopy, adenoma detection rate
Ligamentum Teres Tenodesis in Developmental Dysplasia of the Hip

Study Overview
=================
Brief Summary
-----------------
The treatment of developmental dysplasia of the hip (DDH) remains challenging, yet recent advances have refined our understanding of how best to survey for the condition during infancy, minimize complications during early treatment, and refine the selection of patients who can best benefit from hip preservation surgery. The ideal continued target would be to prevent missed hip dislocations or dysplasia during the infant period, prevent avascular necrosis (AVN) during early treatment, and decrease the incidence of total hip arthroplasty in adulthood related to undertreated DDH, The goal of the treatment is to achieve a concentric reduction of the femoral head into the acetabulum.

Detailed Description
-----------------
it is an operative technique to secure the femoral head after reduction in cases of developmental dysplasia of the hip Operative technique: The surgery will be accomplished under a general anesthesia. An addition to the steps of the open reduction, the following were done: Identification of ligamentum teres ligamentum teres tenodesis

Official Title
-----------------
The Role of Ligamentum Teres Tenodesis in the Management of Developmental Dysplasia of the Hip

Conditions
-----------------
Orthopedic Disorder

Intervention / Treatment
-----------------
* Other: ligamentum teres tenodesis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient with Developmental dysplasia of the hip (DDH) with : Age: from 9 months -5 years old. Virgin DDH. Failed closed reduction in the management of DDH. Failed open reduction through medial approach in the management of DDH Exclusion Criteria: • Paralytic hip dislocation . Post septic hip dislocation. Traumatic hip dislocation . Age : below 9 months or above 5 years. Refusal to participate in this study.

Ages Eligible for Study
-----------------
Minimum Age: 9 Months
Maximum Age: 60 Months

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: ligamentum teres tenodesis|Identification of ligamentum teres ligamentum teres tenodesis|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| modified HHS | score for function of the hip | 6 months |
Resting Energy Expenditure Equations in Amyotrophic Lateral Sclerosis, Creation of a ALS-specific Equation

Study Overview
=================
Brief Summary
-----------------
Introduction: Resting energy expenditure (REE) formulas for healthy people (HP) are used to calculate REE (cREE) in amyotrophic lateral sclerosis (ALS) patients. In ALS an increase of measured REE (mREE) in indirect calometry (IC) compared to cREE is found in 50-60%. The aims were (i) to assess accuracy of cREE assessed using eleven formulas as compared to mREE and (ii) to create if needed a specific cREE formula for ALS patients. Method: ALS patients followed in the ALS expert center of Limoges between 1996 and 2014 and with a nutritional evaluation were included. mREE assessed with IC and cREE calculated with eleven predictive formulas (Harris Benedict (HB) 1919, HB 1984, WSchofield, De Lorenzo, Johnstone, Mifflin, WHO/FAO, Owen, Fleisch, Wang and Rosenbaum) were collected at time of diagnosis. Fat free mass (FFM) and fat mass (FM) were measured with impedancemetry. A Bland and Altman analysis was carried out. The percentage of accurate prediction ± 10%of mREE, and intraclass correlation coefficients (ICC) were calculated. Using a derivation sample, a new REE formula was created using multiple linear regression according to sex, age, FFM and FM. Accuracy of this formula was assessed in a validation sample.

Official Title
-----------------
Resting Energy Expenditure Equations in Amyotrophic Lateral Sclerosis, Creation of a ALS-specific Equation

Conditions
-----------------
Amyotrophic Lateral Sclerosis

Intervention / Treatment
-----------------
* Other: nutritional assessement


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ALS diagnosed patients according to Airlie House criteria treated with riluzole respiratory quotient (RQ) of patients in indirect calorimetry (IC) should be in between 0.7 and 0.87 Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: nutritional assessement|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Resting energy expenditure emeasures |  | nutritional assessement should have been be performed within a 1.5 months' time period. IC had to be performed no later than 12 months after diagnosis. |
Adaptation of the One-session CBT Protocol for Prevention of Mental Illness for Brazilian Portuguese

Study Overview
=================
Brief Summary
-----------------
Recruitment of medicine students of federal university. Psychiatric interview (MINI) and sclaes application. Protocol of CBT Scales and MINI will be applied at the times of 7, 30 and 90 days after the end of the therapy. Statistical analysis

Official Title
-----------------
Adaptation of the One-session CBT Protocol for Prevention of Mental Illness for Brazilian Portuguese: Open Clinical Trial

Conditions
-----------------
CBT, Mental Disorder

Intervention / Treatment
-----------------
* Other: Cognitive Behavioral Therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: be medical student be over 18 years of age agree to the Term of Free and Informed Consent. Exclusion Criteria: Students with psychotic illness, severe depression, manic episode or acute psychiatric risk.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Medical Students<br>Cognitive Behavioral Therapy Protocol | Other: Cognitive Behavioral Therapy<br>* One-Session Unified Protocol<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevention of anxiety symptoms | Overall Anxiety Severity and Impairment Scale (OASIS). It is a 5-item self-report measure that can be used to assess severity and impairment associated with any anxiety disorder. Respondents select among five different response options for each item, which are coded 0-4 and summed to obtain a total score. A cut-score of 8 correctly classified 87% of this sample as having an anxiety diagnosis or not. | 90 days after | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevention of depression symptoms | Beck Depression Inventory (BDI). It is a 21-question multiple-choice self-report inventory for measuring the severity of depression. Each question had a set of at least four possible (0 to 3) responses, ranging in intensity. Scores: 0-9: indicates minimal depression, 10-18: indicates mild depression, 19-29: indicates moderate depression, 30-63: indicates severe depression. | 90 days after |
Risk Factors For Asthma in Laboratory Animal Allergy

Study Overview
=================
Brief Summary
-----------------
To identify risk factors which predispose individuals to develop asthma and other manifestations of allergic disease on exposure to laboratory animals in the workplace.

Detailed Description
-----------------
BACKGROUND: In 1982, asthma and allergy to laboratory animals among persons who worked with the animals gained increased recognition as an occupational health problem affecting researchers, veterinarians, technicians, animal handlers, and others. At that time, more than 90,000 workers across the United States were at risk due to their exposure to lab animals in the more than 1,100 facilities registered by the United States Department of Agriculture. Several surveys of exposed workers indicated a prevalence rate of allergic symptoms due to laboratory animal allergy ranging from 19-30 percent in animal workers. Asthma was also a frequent disease among animal workers; these surveys indicated that as many as 13-14 percent of exposed workers had asthma. The problem of laboratory animal allergy and asthma involved a vast industry that included medical and veterinary colleges, research institutes and universities, pharmaceutical manufacturers, commercial laboratory animal producers, and hospitals. DESIGN NARRATIVE: Recruitment for this longitudinal study began in November 1983 and ended in July 1987. The initial visit consisted of an extensive interview to identify and to exclude those individuals with laboratory animal allergy, asthma, and other manifestations of allergy and to obtain an occupational history. Venipuncture was used to obtain serum for IgE and IgG antibody assays. Pulmonary function tests, including a methacholine challenge, were administered. Psychosocial questionnaires were administered. Subjects were evaluated at six month intervals with skin tests, venipuncture, and methacholine challenge. The degree of exposure to animal allergens was quantitated by aeroallergen sampling of workplace and personal breathing zone air and by work diaries. The study completion date listed in this record was obtained from the End Date entered in the Protocol Registration and Results System (PRS) record.

Conditions
-----------------
Asthma, Lung Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
No eligibility criteria

Ages Eligible for Study
-----------------
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Phase IB Study Using Sunitinib Plus Radiation Therapy for Cancer Patients

Study Overview
=================
Brief Summary
-----------------
This study is using the combination of radiation and antiangiogenic agents (agents that destroy existing blood vessels) seems to be an approach to tumor cure.

Detailed Description
-----------------
The combination of ionizing radiation and antiangiogenic agents seems to be a counterintuitive approach to tumor cure because oxygen is a potent radiosensitizer and a reduction in oxygen concentration would be expected following a reduction in tumor vasculature after antiangiogenic treatment.

Official Title
-----------------
A Phase IB, Open-Label, Safety Study of the Combination of Sunitinib and Radiation for the Treatment of Patients With Cancer

Conditions
-----------------
Cancer, Head and Neck Cancer, Pelvic Cancer, Nervous System Neoplasms, Thoracic Neoplasms

Intervention / Treatment
-----------------
* Drug: Sunitinib
* Radiation: External Beam Radiation Therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Minimum 2 week course of radiation therapy Solid tumors of the central nervous system, head and neck, thorax, and pelvis Exclusion Criteria: Major surgery or radiation therapy within 4 weeks starting study treatment Grade 3 hemorrhage within 4 weeks

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Sunitinib plus Radiation<br>Sunitinib plus Radiation | Drug: Sunitinib<br>* The use of the FDA approved drug sunitinib, used in an off-label manner with external beam radiation therapy.<br>* Other names: SU11248;Radiation: External Beam Radiation Therapy<br>* Radiotherapy will be administered Monday through Friday for a maximum of 8 weeks. Total dose will depend on the patient's disease site.<br>* Other names: Teletherapy;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate the safety and toxicity profile of sunitinib when used with concurrent radiation therapy | The purpose of this study is to determine the safety of the combination of the antiangiogenic, sunitinib, when combined with external beam radiotherapy. | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To measure urine VEGF | Urine VEGF may be a biomarker of response. This translational approach may be useful to determine who benefits from treatment. | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
solid tumor, central nervous system, head and neck, thorax, pelvic area
Effect of Transparent, Self-drying Silicone Gel on the Treatment of Hypertrophic Abdominal Scars

Study Overview
=================
Brief Summary
-----------------
Keloids and hypertrophic scars are a common subject of dermatologic consultations. Therapeutic management of such conditions remains challenging because of their high rate of recurrence and lack of curative treatment.

Detailed Description
-----------------
Silicone gel Sheeting (SGS) is one treatment modality that has proven effective for treatment of hypertrophic scar. One disadvantage of SGS is its application technique. To be effective, SGS must be applied on the scar for at least 12 hours daily. Topical silicone gel is a novel therapy that has shown promising result on scar prevention. However, the efficacy and safety of topical silicone gel for treatment of hypertrophic scar has not been confirmed.

Official Title
-----------------
Effect of Transparent, Self-drying Silicone Gel on the Treatment of Hypertrophic Abdominal Scars

Conditions
-----------------
Keloids, Hypertrophic Scars

Intervention / Treatment
-----------------
* Other: Topical silicone gel
* Other: Vaseline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: subjects at least 18 years old subjects with hypertrophic abdominal scar Have not received treatment on the scar at least 1 month prior to the enrollment. Exclusion Criteria: subject who has previous history of silicone allergy subject who smoke cigarette subject who was treated with x-rays irradiation in the past

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Silicone gel<br>Gel containing silicone gel | Other: Topical silicone gel<br>* Topical silicone gel will be applied to the scar twice daily for a period of 8 weeks<br>* Other names: Dermatix gel;|
| Placebo Comparator: Vaseline<br>Gel containing petrolatum gel | Other: Vaseline<br>* Topical petrolatum gel will be applied to the scar twice daily for a period of 8 weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Scar thickness |  | 1, 2 and 5 months after initiation of treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical assessment on overall scar appearance |  | 1, 2 and 5 months after initiation of treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hypertrophic scars, Topical silicone gel, Scar thickness, Scar Color, Scar pliability, Scar appearance
Myocardial and Renal Dysfunction by Oxidative Stress Caused by Cardiac Surgery

Study Overview
=================
Brief Summary
-----------------
Assessment of the severity of oxidative stress caused by the on-pump and off-pump cardiac surgery using mtDNA, nDNA, carbonilated proteins, nitrotyrosine, oxy-LDL, S100b-protein.

Official Title
-----------------
Myocardial and Renal Dysfunction by Oxidative Stress Caused by Cardiac Surgery

Conditions
-----------------
Reperfusion Injury

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: shedduled CABG Exclusion Criteria: stroke befor surgery miocardial infarction 6 monthes befor surgery dementia liver cirrhosis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| valve surgery<br>valve plasty/replacement surgery | |
| off-pump CABG<br>off-pump CABG | |
| CPB-CABG<br>CABG with CardioPulmonal Bypass | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assay of mtDNA |  | from baseline whithin 72 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assay of nDNA |  | from baseline whithin 72 hours | 
| Assay of carbonilated proteins |  | from baseline whithin 72 hours | 
| Assay of nitrotyrosine |  | from baseline whithin 72 hours | 
| Assay of oxy-LDL |  | from baseline whithin 72 hours | 
| Assay of S100b-protein |  | from baseline whithin 72 hours |
Influence of Intensive Lipid Lowering Treatment Compared to Moderate Lipid Lowering Treatment

Study Overview
=================
Brief Summary
-----------------
The aim of this study was to measure the effect of low- and high-dose lipid-lowering treatment with rosuvastatin on the coronary physiology parameters.

Official Title
-----------------
Effect of Intensive Lipid Lowering Treatment Compared to Moderate Lipid Lowering Treatment on the Coronary Microcirculation

Conditions
-----------------
Myocardial Infarction [C14.907.585.500]

Intervention / Treatment
-----------------
* Drug: Low-dose Rosuvastatin
* Drug: High-dose Rosuvastatin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ST-segment elevation myocardial infarction no prior treatment with statins and a non significant lesion in one of the two non-culprit coronary arteries Exclusion Criteria: age below 18 or above 81 years, unconscious patients, serum creatinine > 176μmol/L, hypothyroidism ((TSH > 1.5 x ULN (upper limit of normal)), current liver disease (ALAT > 2 x ULN), unexplained creatine kinase > 3 x ULN, alcohol or drug abuse within the last five years, prior myopathy or serious hypersensitivity reaction caused by statins, women with childbearing potential who were not using chemical or mechanical contraception, pregnant or breastfeeding women, history of malignancy unless a disease-free period of more than five years was present, patients with abnormal lung function test (LFT), participation in another investigational drug study less than four weeks before enrolment in the present study, treatment with cyclosporine or fibrates

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 81 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Low-dose Rosuvastatin<br>5mg Rosuvastatin/day | Drug: Low-dose Rosuvastatin<br>* Rosuvastatin 5mg/day for one year<br>* Other names: Crestor;|
| Active Comparator: High-dose Rosuvastatin<br>Rosuvastatin 40mg/day | Drug: High-dose Rosuvastatin<br>* Rosuvastatin 40mg/day for one year<br>* Other names: Crestor;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The primary endpoint was the change from baseline in Index of microcirculatory resistance(IMR). |  | One year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The secondary endpoints were the changes from baseline in Fractional Flow Reserve (FFR) and lipid values. |  | One year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Index of microcirculatory resistance, Fractional Flow Reserve